logo
Twitter
Discord
Email
logo
Geron Corporation

Geron Corporation

NASDAQ•GERN
CEO: Dr. John A. Scarlett M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 1996-07-31
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Contact Information
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States
650-473-7700
www.geron.com
Market Cap
$836.25M
P/E (TTM)
-11.9
40.1
Dividend Yield
--
52W High
$3.12
52W Low
$1.04
52W Range
13%
Rank56Top 81.7%
2.5
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$47.23M+67.05%
4-Quarter Trend

EPS

-$0.03-30.83%
4-Quarter Trend

FCF

-$13.49M-77.12%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

RYTELO Net Revenue Surges Nine months product revenue reached $135.610M, marking a 368% increase compared to $28.989M in prior year period.
Operating Loss Significantly Narrows Nine months loss from operations improved to $(43.045)M versus $(153.682)M previously, driven by strong revenue uptake.
Strong Liquidity Position Maintained Total cash, equivalents, and marketable securities stood at $421.5M as of September 30, 2025, supporting operations.
Inventory Rises for Sales Total inventory increased to $95.422M by September 30, 2025, up from $38.714M at year-end 2024, supporting commercial supply.

Risk Factors

Material Weakness in Controls Material weakness identified in ITGCs related to ERP and payment systems; remediation efforts expected completion by fourth quarter 2025.
RYTELO Commercialization Uncertainty Near-term prospects wholly dependent on RYTELO success; limited experience in commercializing product outside U.S. markets remains a key challenge.
Ongoing Securities Litigation Risk Securities class action and derivative lawsuits pending; outcomes are uncertain and defense costs could require substantial resources.
Debt Covenants Limit Flexibility Pharmakon Loan Agreement imposes operating restrictions; failure to meet covenants could trigger immediate repayment of $125.0M Tranche A debt.

Outlook

EU Commercialization Planning Preparing for planned RYTELO commercialization in select EU markets starting in 2026; seeking experienced third parties for launch support.
Increased R&D Spending Expected Expect research and development expenses to increase in Q4 2025 due to ongoing investments supporting CMC strategy and IMpactMF trial completion.
SG&A Expenses Projected Higher Expect selling, general and administrative expenses to increase over remainder of year due to continued investment in RYTELO U.S. commercialization strategy.
Funding Sufficient for Near Term Current cash position, combined with anticipated net revenues from U.S. RYTELO sales, is believed sufficient for projected operating requirements.

Peer Comparison

Revenue (TTM)

Valneva SEVALN
$198.55M
+13.5%
Geron CorporationGERN
$183.40M
+522.1%
Ginkgo Bioworks Holdings, Inc.DNA
$180.61M
-17.1%

Gross Margin (Latest Quarter)

Arbutus Biopharma CorporationABUS
97.9%
-2.1pp
UroGen Pharma Ltd.URGN
85.3%
-4.5pp
Kura Oncology, Inc.KURA
84.5%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TYRA$1.54B-16.2-31.8%1.9%
URGN$928.17M-6.6503.5%60.3%
ABUS$910.95M-20.4-50.2%0.9%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.2%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-$0.03
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 7, 2025|
    Revenue: $47.23M+67.1%
    |
    EPS: $-0.03-30.8%
    Meet

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $49.04M+5459.6%
    |
    EPS: $-0.02-75.4%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $39.60M+12927.3%
    |
    EPS: $-0.03-67.3%
    Meet

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $76.99M+32386.9%
    |
    EPS: $-0.27+15.6%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $28.27M+17138.4%
    |
    EPS: $-0.04-48.4%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $882.00K+2941.4%
    |
    EPS: $-0.10+11.2%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $304.00K+1347.6%
    |
    EPS: $-0.09+31.3%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $237.00K-60.2%
    |
    EPS: $-0.32+13.5%
    Miss